SAN DIEGO, June 24 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego based medical device company, today announced that it has established a distribution partnership in the Spanish market through SIM, a Madrid based firm specializing in the marketing and distribution of innovative medical devices.
Michel Vaudry, SpectraScience's VP of Sales and Marketing, said, "We are pleased to add another distribution partner in Europe. SIM is a respected and well established medical distribution company and adding the WavSTAT Optical Biopsy System to their portfolio is a strong validation of the need for our technology. SIM was established in 2000 and distributes other leading gastroenterological diagnostic products from market leaders including PENTAX and ERBE."
SIM's Consejero Delegado, Jose Manuel Ruiz, stated that, "We are pleased to be SpectraScience's distribution partner and believe there is significant market potential for this innovative gastrointestinal cancer diagnostic system. Our strategy is to be the leader in gastro-diagnostics and the WavSTAT Optical Biopsy System is an ideal fit with our PENTAX endoscopes. We see important benefits to our physicians, enabling them to quickly distinguish between normal and precancerous tissue in the GI tract and allowing for physical biopsy at exactly the same site and time that an optical biopsy is performed. More importantly, the WavSTAT objectively identifies the borders of tissue during surgery to determine if all cancerous tissue has been removed. This can prevent additional costly treatment."
Vaudry added, "Mr. Ruiz is a respected thought leader in the healthcare market and his company's support of the WavSTAT System will be instrumental in our acceptance at the major gastroenterology centers in Spain. SIM is a perfect partner for SpectraScience as they also represent PENTAX. PENTAX is one of the leading manufacturers of endoscopes which are used in conjunction with our product."
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.
About SpectraScience, Inc.
SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provides the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. In addition, the Company's LUMA(R) Cervical Imaging technology has received FDA approval as an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available today.
Contact: SpectraScience, Inc. Hayden Communications Jim Hitchin, Chief Executive Officer Investor Relations (858) 847-0200 x 201 Todd Pitcher http://www.spectrascience.com (858)-518-1387
|SOURCE SpectraScience, Inc.|
Copyright©2009 PR Newswire.
All rights reserved